Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Among authors: de azambuja e. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Adjuvant chemotherapy in 2005: standards and beyond.
Piccart MJ, de Valeriola D, Dal Lago L, de Azambuja E, Demonty G, Lebrun F, Bernard-Marty Ch, Colozza M, Cufer T. Piccart MJ, et al. Among authors: de valeriola d, de azambuja e. Breast. 2005 Dec;14(6):439-45. doi: 10.1016/j.breast.2005.08.004. Epub 2005 Sep 26. Breast. 2005. PMID: 16188441 Review.
Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Among authors: de azambuja e. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
Molecular targeted therapies in breast cancer: where are we now?
Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Widakowich C, et al. Among authors: de azambuja e. Int J Biochem Cell Biol. 2007;39(7-8):1375-87. doi: 10.1016/j.biocel.2007.04.015. Epub 2007 May 4. Int J Biochem Cell Biol. 2007. PMID: 17543572 Review.
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team. Untch M, et al. Among authors: de azambuja e. Ann Oncol. 2008 Jun;19(6):1090-6. doi: 10.1093/annonc/mdn005. Epub 2008 Feb 21. Ann Oncol. 2008. PMID: 18296421 Free article. Clinical Trial.
312 results